To date, clinical trials involving CTLA‐4 and PD‐1 inhibitors have shown limited efficacy in treating synovial sarcoma, with response rates falling below 10%.[22, 23, 46] However, with the swift advancements in immune checkpoint inhibitor therapies, these findings pave the way for a more in‐depth exploration of potential immunotherapy for SS. This evidence concerns the gene PDCD1 and synovial sarcoma.